John N Renneburg Jr, MD | |
1 Lyons St, Dedham, MA 02026-5599 | |
(781) 329-1400 | |
(781) 461-8691 |
Full Name | John N Renneburg Jr |
---|---|
Gender | Male |
Speciality | Allergy & Immunology |
Location | 1 Lyons St, Dedham, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861466716 | NPI | - | NPPES |
5930251 | Other | AETNA US HEALTHCARE | |
J13537 | Other | BLUE SHIELD HMO BLUE | |
3100588 | Other | MEDICAID WELFARE | |
784075 | Other | MVP HEALTH CARE | |
919279 | Other | FIRST HEALTH | |
AA2169 | Other | HARVARD PILGRIM HEALTHCAR | |
27197 | Other | HEALTHY START | |
J13537 | Other | BLUE CARE ELECT | |
J13537 | Other | MEDICARE B | |
3100588 | Medicaid | MA | |
9900291 | Other | FALLON COMMUNITY HEALTH P | |
J13537 | Other | BLUE SHIELD INDEMNITY | |
0200021 | Other | EVERCARE | |
7107816 | Other | CIGNA HEALTH PLAN | |
27197 | Other | CHILDRENS MEDICAL SECURIT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | 70756 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
John N Renneburg Jr, MD 1 Lyons St, Dedham, MA 02026-5599 Ph: (781) 329-1400 | John N Renneburg Jr, MD 1 Lyons St, Dedham, MA 02026-5599 Ph: (781) 329-1400 |
News Archive
Vaccines to protect against an avian influenza pandemic as well as seasonal flu may be mass produced more quickly and efficiently using technology described today (Sept. 2) by researchers at the University of Wisconsin-Madison in the journal Nature Communications.
Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.
Sepsis, or septicaemia, is a devastating disease that is difficult to diagnose early and for which treatment options are limited. The number of deaths from sepsis exceeds those from lung cancer, and from breast and bowel cancer combined.
› Verified 6 days ago